

● c'd PCT/PTO 10 FEB 2005 ●

RECEIVED

15 DEC 2004

PATENT COOPERATION TREATY

PCT

INTERNATIONAL PRELIMINARY REPORT ON PATENTABILITY
(Chapter II of the Patent Cooperation Treaty)

(PCT Article 36 and Rule 70)

CODE	DATE	NTD
ANKOM 13 DEC 2004 GIPS		
DATA ENTERED		
FINAL CHECK		

Applicant's or agent's file reference 100653-1 WO	FOR FURTHER ACTION See Form PCT/	
International application No. PCT/SE2003/001279	International filing date (day/month/year) 13.08.2003	Priority date (day/month/year) 14.08.2002
International Patent Classification (IPC) or national classification and IPC C07D 471/04, A61K 31/437, A61P 37/08, A61P 11/06		
Applicant AstraZeneca AB et al		

- This report is the international preliminary examination report, established by this International Preliminary Examining Authority under Article 35 and transmitted to the applicant according to Article 36.
- This REPORT consists of a total of 4 sheets, including this cover sheet.
- This report is also accompanied by ANNEXES, comprising:
 - ☐ (sent to the applicant and to the International Bureau) a total of _____ sheets, as follows:
 - ☐ sheets of the description, claims and/or drawings which have been amended and are the basis of this report and/or sheets containing rectifications authorized by this Authority (see Rule 70.16 and Section 607 of the Administrative Instructions).
 - ☐ sheets which supersede earlier sheets, but which this Authority considers contain an amendment that goes beyond the disclosure in the international application as filed, as indicated in item 4 of Box No. I and the Supplemental Box.
 - ☐ (sent to the International Bureau only) a total of (indicate type and number of electronic carrier(s)) _____, containing a sequence listing and/or tables related thereto, in computer readable form only, as indicated in the Supplemental Box Relating to Sequence Listing (see Section 802 of the Administrative Instructions).

- This report contains indications relating to the following items:

<input checked="" type="checkbox"/> Box No. I	Basis of the report
<input type="checkbox"/> Box No. II	Priority
<input type="checkbox"/> Box No. III	Non-establishment of opinion with regard to novelty, inventive step and industrial applicability
<input type="checkbox"/> Box No. IV	Lack of unity of invention
<input checked="" type="checkbox"/> Box No. V	Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement
<input type="checkbox"/> Box No. VI	Certain documents cited
<input type="checkbox"/> Box No. VII	Certain defects in the international application
<input type="checkbox"/> Box No. VIII	Certain observations on the international application

Date of submission of the demand 27.02.2004	Date of completion of this report 02.12.2004
Name and mailing address of the IPEA/SE Patent- och registreringsverket Box 5055 S-102 42 STOCKHOLM Facsimile No. +46 8 667 72 88 Form PCT/IPEA/409 (cover sheet) (January 2004)	Authorized officer Solveig Gustavsson/EÖ Telephone No. +46 8 782 25 00

BEST AVAILABLE COPY

INTERNATIONAL PRELIMINARY REPORT ON PATENTABILITY

International application No.

PCT/SE2003/001279

Box No. I Basis of the report

1. With regard to the language, this report is based on the international application in the language in which it was filed, unless otherwise indicated under this item.

☐ This report is based on a translation from the original language into the following language _____, which is the language of a translation furnished for the purposes of:

- ☐ international search (under Rules 12.3 and 23.1(b))
☐ publication of the international application (under Rule 12.4)
☐ international preliminary examination (under Rules 55.2 and/or 55.3)

2. With regard to the elements of the international application, this report is based on *(replacement sheets which have been furnished to the receiving Office in response to an invitation under Article 14 are referred to in this report as "originally filed" and are not annexed to this report)*:

☒ the international application as originally filed/furnished

☐ the description:

pages _____ as originally filed/furnished

pages* _____ received by this Authority on _____

pages* _____ received by this Authority on _____

☐ the claims:

pages _____ as originally filed/furnished

pages* _____ as amended (together with any statement) under Article 19

pages* _____ received by this Authority on _____

pages* _____ received by this Authority on _____

☐ the drawings:

pages _____ as originally filed/furnished

pages* _____ received by this Authority on _____

pages* _____ received by this Authority on _____

☐ a sequence listing and/or any related table(s) – see Supplemental Box Relating to Sequence Listing.

3. ☐ The amendments have resulted in the cancellation of:

☐ the description, pages _____

☐ the claims, Nos. _____

☐ the drawings, sheets/figs _____

☐ the sequence listing (*specify*): _____

☐ any table(s) related to the sequence listing (*specify*): _____

4. ☐ This report has been established as if (some of) the amendments annexed to this report and listed below had not been made, since they have been considered to go beyond the disclosure as filed, as indicated in the Supplemental Box (Rule 70.2(c)).

☐ the description, pages _____

☐ the claims, Nos. _____

☐ the drawings, sheets/figs _____

☐ the sequence listing (*specify*): _____

☐ any table(s) related to the sequence listing (*specify*): _____

* If item 4 applies, some or all of those sheets may be marked "superseded."

INTERNATIONAL PRELIMINARY REPORT ON PATENTABILITY

International application No.

PCT/SE2003/001279

Box No. V Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement

1. Statement

Novelty (N)	Claims	<u>1-19</u>	YES
	Claims	_____	NO
Inventive step (IS)	Claims	_____	YES
	Claims	<u>1-19</u>	NO
Industrial applicability (IA)	Claims	<u>1-19</u>	YES
	Claims	_____	NO

2. Citations and explanations (Rule 70.7)

Cited documents:

D1) WO 0196336 A2

D2) EP 0049407 A1

The claimed invention relates to novel compounds and to the use of these and some known compounds as Itk inhibitors for the treatment of asthma and allergic rhinitis.

The document D1 is regarded as being the closest prior art and discloses compounds that are overlapping with the compounds of the present claims. These compounds are used for the treatment of asthma (see claim 40).

Some (3H-imidazo[4,5-b]pyridine-2-yl)-phenyl derivatives are explicitly mentioned (see claim 30), but no compounds falling under the formulas of claims 1 (formula 1), 9 (formula 1a), 11 (formula 1b), 13 (formula 1c) or 15 (formula 1d) are exemplified in D1.

Therefore, the subject matter of claims 1-19 is novel.

The subject-matter of the claimed invention differs from what is known from D1 in that the known structurally related compounds are said to inhibit the 15-lipoxygenase enzyme instead of the kinase Itk although they are both used for treatment of asthma.

The applicant has not shown that the structural differences render the claimed compounds unexpected effects in comparison with the known compounds.

It is considered obvious to a person skilled in the art to modify structurally similar compounds to obtain the claimed

.../...

INTERNATIONAL PRELIMINARY REPORT ON PATENTABILITY

International application No.

PCT/SE2003/001279

Supplemental Box

In case the space in any of the preceding boxes is not sufficient.

Continuation of: BOX V

compounds and come to the conclusion that they will have the same activity.

Thus, claims 1-19 are considered to fulfil the requirement of novelty, but not that of inventive step.